Regulatory & Legal

Zepto Life Technology's FDA Breakthrough status for a fungal test isn't just a win for patients; it's a strategic move in liquid biopsy's new frontier.

The struggling biopharma secures cash, but its creative financing deal could dilute existing shareholder value by over 30%. A deep dive into the high-stakes world of biotech funding.

A new $515M contract for the SPY-6 radar is more than a sale; it's a strategic play cementing U.S. tech dominance and revitalizing domestic manufacturing.

A new partnership between 700Credit and Quotible promises to streamline auto sales by putting financing first, offering a glimpse into a future of faster, more transparent deals.

Insulet's latest Omnipod 5 enhancements are more than a software update; they're a strategic move in the diabetes tech race. Here's what it means.

Peyto's 10-year deal with Centrica links Alberta gas to European prices. It's a masterclass in strategy, but the real story is the invisible journey ahead.

A new lawsuit over atmospheric plasma technology could disrupt supply chains for AI chips and medical devices, highlighting fierce IP battles in high-tech.

Alamos Gold's plan to expand its Manitoba mine raises new questions about balancing economic gains with environmental and Indigenous community impacts.

Largest shareholder Al Shams Investments demands a shareholder meeting, alleging Braemar's board is captive to its advisor amid a high-stakes strategic review.

SOCRadar's 'Best Workplace' award isn't just an HR win. It's the strategic core fueling its AI innovation and rapid growth in a talent-starved industry.

A call for research on vaccine side effects exposes a deeper crisis: the collapse of public trust in science. Can rigorous data heal a polarized nation?

Bluejay Diagnostics secures critical funding to advance its rapid sepsis test, extending its cash runway but raising questions about shareholder dilution.

A press release announced a bright new chapter for DBH. The real story? A $280M debt default, a lender takeover, and a new CEO's daunting mission.

Tinkerine Studios is cleaning house to merge with Fotonara, a tech firm promising data privacy and efficiency. Is this the rebirth of a company or just another RTO gamble?

Nephrodite's implantable dialysis system just entered a key FDA program, signaling a major shift in treating kidney failure. Is freedom from the dialysis chair finally in sight?

A delayed financial report and a plea for a trading halt for its own executives place Premier Health under a harsh spotlight, signaling deeper financial distress.

A burgeoning market for cervical dystonia is set for disruption. A pipeline of novel therapies, including oral options, promises to address unmet patient needs.

An Israeli-American tech firm just put AI eyes on a US Black Hawk, pioneering a new era of visual predictive maintenance that could transform aviation safety.

As AI weaponizes our personal data, your social media is the new frontline. Kanary’s new tools highlight a critical shift in security: protecting people to protect the enterprise.

When an uninsured driver vanishes after a crash, the system can fail victims. A recent case reveals how private investigation is changing the odds.